OUR VISION
Strategically positioned to bridge the East and West, Esco aspires to become the leading provider of life science and fertility tools, delivering sustainable technologies that foster a healthier, more equitable, and resilient future.
OUR MISSION
We provide cutting-edge, sustainable workflow solutions that empower scientists and innovators to advance global health and enhance quality of life.
VALUE PROPOSITION
We deliver innovative, high-value equipment and technologies tailored to the life science and medical markets.
Our commitment to excellence ensures top-quality products and outstanding service.
ACCCG
Attitude
Communication
Competence
Commitment
Growth
Milestones
Esco Lifesciences Group
1978 - 1997
Pioneering Cleanroom Technology in Southeast Asia
Esco was founded in 1978 by Singaporean pharmacists Lim Lay Yew and Low Yae Foong. Esco was launched to manufacture cleanroom products for Singapore’s then-booming electronics industry. In its early days, Esco manufactured its first laminar flow clean bench. During this time, Esco also designed and built its first microelectronics class 10,000 cleanroom for Siemens Corporation. The business expanded as Esco embarked on distribution to the pharmaceutical, life science, biotechnology, and medical research markets in Malaysia and Indonesia with the establishment of Esco Micro (M) Sdn Bhd and PT Esco Bintan Indonesia.
2000 - 2005
Transformation into a Life Sciences Tools Company
In 2000, Esco successfully adapted to the field shifting towards the life sciences. The company quickly transformed itself and earned a reputation for producing and providing laboratory and biological safety equipment. Esco became the first Asian manufacturer to earn EN 12469 certification for biological safety cabinets in 2001 and achieved its first NSF/ANSI certification in 2004. In 2005, Esco was invited by the Chinese Food and Drug Administration to participate in a joint committee to develop the National Standard for Biological Safety Cabinets.
2006 - 2008
Expansion of Operations
To expand the sales of its biological safety cabinets to the global market, Esco set up operations in the United States with the establishment of Esco Technologies, Inc. as an integrated sales, marketing, and distribution center. Offices were also set up in China, Northern America, the Middle East, and Africa. This was followed by a global marketing program (Esco. World Class. Worldwide) to establish its presence as a global life sciences tools company. In 2007, annualized production exceeded 10,000 units.
2009
Esco launches its Pharma Division
Following the success of its biological safety cabinets, Esco established Esco Pharma to expand its repertoire of life sciences tools to include Isotherm® ovens and incubators, Pharmacon™ downflow booths, Swift® MaxPro and MiniPro new-generation PCR thermal cyclers, Labculture® In Vitro Fertilization Workstations, the CelCulture® range of carbon dioxide incubators, and the Lexicon® range of Ultra-low Temperature Freezers.
2012
Esco launches its Medical Division
Esco launched the Esco Medical Division to offer world-class ART/IVF solutions worldwide, with a focus on the new MIRI® Multi-room Incubator. As the IVF MedTech business unit of the Esco Group, Esco Medical provides innovative solutions to fertility clinics and laboratories.
2013 - 2014
New generation life sciences tools
By applying innovative technologies, Esco launched a new range of life sciences tools which include the Airstream® G3 Class II (the greenest low noise biological safety cabinet in the world), the eSafe® BSC (technologically and ergonomically advanced TUV-NORD certified BSC), the MIRI® GA gas and temperature validation unit, the Multi-zone ART Workstation, and the MIRI® Time-Lapse incubator.
2015 - 2018
Esco ventures into Medtech and Biotechnology
In 2016, Esco Healthcare was launched as an umbrella for Esco Pharma, Esco VacciXcell, and Esco TaPestle Rx. The technologies developed from Esco Healthcare were cumulated to establish Esco Aster, the bioprocessing division of the Esco Group of Companies that provides biomanufacturing of vaccines and biologics.
Esco has also invested RMB 100 million into a new 20,000m² Innovation Center in Taicang, China while, at the same time, setting up a venture office in Esco Beijing. Throughout the years, Esco has been given the Singapore Prestige Brand Award for 3 consecutive years and the Top Employer Brand Award, which is a testament to its commitment to its core values and its mission to improve lives through science.
2020 - 2021
Embarking on the Esco 3.0 Transformation
​In 2020, Esco Group of Companies rebranded as Esco Lifesciences Group with the new tagline, “Improving Lives Through Science,” and introduced the laboratory division as Esco Scientific.
​
During the COVID-19 pandemic, Esco ensured an uninterrupted supply of essential products and services, supporting global customers with thousands of biosafety cabinets, PCR cabinets, freezers, and other critical equipment. The company also launched the Trace, Test, and Treat Platform to aid pandemic relief efforts worldwide.
In 2021, we secured a USD 200 million Series A funding round co-led by Vivo Capital and Novo Holdings, with participation from GIC, EDBI, China Investment Corporation (CIC), and other leading investors. Building on this strong foundation, Esco embarks on our Esco 3.0 transformation, focusing on disciplined M&A, strengthening core capabilities, and expanding into new markets.
2022 - 2023
Accelerating Global Expansion and Innovation Through Acquisitions
In 2022, Esco Lifesciences Group expanded its global presence with the acquisition of Evidence Solution, a Danish software company specializing in IVF management and quality systems. In the same year, we established a dedicated Healthcare business unit in China and expanded our manufacturing footprint in the country to 200,000 sq. ft.
Esco also introduced multiple innovative products, including Touchscreen Biosafety Cabinets, Animal Research Workstations, and COâ‚‚ Incubators. With strengthened manufacturing capabilities in China and Europe, and the launch of the Esco Business System, our unique operational framework, Esco is well-positioned for continued growth to serve our customers worldwide.
​​
​
2024 - 2025
Delivering Sustainable Workflow Solutions to Advance Global Health
In 2024, Esco Lifesciences Group launched operations at its new 7,900 sqm manufacturing plant in Lithuania, enhancing production capacity and accelerating innovation for Esco Medical Technologies. Esco also acquired its distributor, Esco Korea Micro Ltd., establishing a new subsidiary to strengthen direct sales and service capabilities in the growing market, while driving digital transformation to improve operational efficiency.
In February 2025, Esco Lifesciences Group formed a strategic partnership with Allwin Medical Devices, a leading U.S. manufacturer of IVF consumables. With Esco’s majority stake investment in Allwin, Esco enhances its commitment to delivering sustainable workflow solutions and strengthens its manufacturing capabilities in India.
With these advancements, Esco Lifesciences remains dedicated to delivering sustainable technologies that foster a healthier, more equitable, and resilient future.